Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-01-31

Study Completion Date

2007-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine what factors affect a patient's decision to accept delayed Herceptin® treatment after completing their surgery and/or chemotherapy and/or radiation therapy.

Women with invasive breast cancer that have a HER-2 positive (FISH +) determination in 2004 or thereafter and who have completed surgery and primary treatment earlier will be potentially eligible.

Patients will be asked to complete a questionnaire about their breast cancer and reasons why they may or may not accept Herceptin® treatment. Patients will be given the option to (1) receive Herceptin® for 52 weeks and have annual doctor visits for 5 years or (2) not to receive Herceptin® but agree to annual doctor visits for 5 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer

NCT00047255

Breast Cancer

COMPLETED PHASE3

Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer

NCT01548677

Breast Cancer Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Circulating Tumor Cells

COMPLETED PHASE2

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

NCT01275677

HER2/Neu Positive Progesterone Receptor Positive Recurrent Breast Carcinoma +6 more

COMPLETED PHASE3

Randomized Trial With Trastuzumab Versus Observation in Breast Cancer Patients

NCT00429247

Breast Cancer

COMPLETED PHASE2

A Study To Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

NCT02616224

Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer

WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Phase- Phase II Study Type- Interventional Study Design-

This is an open label, non-randomized phase II study in patients with non-metastatic HER-2 positive breast cancer by FISH diagnosed in 2004 or thereafter. Potential patients will sign a written ICF prior to completing a questionnaire designed to determine what factors may affect a patient's acceptance of Herceptin® treatment. After answering the questionnaire, patients will be given the following options:

1. to receive one year of trastuzumab treatment and annual follow-up for 5 years
2. to decline trastuzumab treatment but serve as a comparison group member for monitoring safety and effectiveness of trastuzumab and to have annual follow-up for 5 years

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Trastuzumab

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Confirmed non-metastatic infiltrating carcinoma of the breast.
2. HER-2 amplified (FISH +) determination in 2004 or thereafter.
3. ECOG performance status 0-2.
4. Patients 18 years of age or older.
5. HER-2 status is determined by FISH test.
6. The following criteria are applicable to the trastuzumab treatment group:

* Normal LVEF as determined by ECHO or MUGA. If baseline LVEF \> 75%, then LVEF shall be repeated to determine if falsely elevated.
* Adequate bone marrow function as indicated by the following: ANC \>1500/mL, Platelets \>/=100,000/mL, Hemoglobin \>9 g/dL
* Adequate renal function,as indicated by serum creatinine \</= 1.5 x ULN
* Adequate liver function, as indicated by total bilirubin \</= 1.5 x ULN
* AST and ALT \< 2 x ULN unless related to primary disease.
* If female of childbearing potential, pregnancy test (blood or urine) is negative and she agrees to use effective birth control method for the duration of the study.
7. Signed informed consent has been obtained.

Exclusion Criteria

1. Non-confirmed HER-2 positive by FISH infiltrating carcinoma of the breast.
2. Evidence of metastatic disease.
3. Previous trastuzumab treatment.
4. Concurrent anticancer treatment other than hormonal agents (tamoxifen, aromatase inhibitors) or radiotherapy.
5. Patient with history of or active cardiac disease, including cardiomyopathy, congestive heart failure, prior myocardial infarction, or arrhythmia.
6. Symptomatic intrinsic lung disease resulting in dyspnea at rest.
7. Concurrent life-limiting disease with a life expectancy of less than one year.
8. Pregnancy, nursing women, and fertile women who do not practice birth control.
9. Inability to give informed consent.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No